Africa Finance Today
SEE OTHER BRANDS

The best finance and banking news from Africa

Africa Finance Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa Finance Today.

Press releases published on May 14, 2025

Reborn Coffee and Tori AI Sign MOU to Implement Smart Retail Technology

Reborn Coffee and Tori AI Sign MOU to Implement Smart Retail Technology

BREA, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Reborn Coffee Inc. (Nasdaq: REBN), a leader in the specialty coffee market, today announced the signing of a Memorandum of Understanding (MOU) with Tori AI, a pioneering artificial intelligence company …

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the impact NeuroStar has as a safe, effective, …

Himax and Vuzix to Showcase Integrated Industry-Ready AR Display Module at Display Week 2025

Himax and Vuzix to Showcase Integrated Industry-Ready AR Display Module at Display Week 2025

TAINAN, Taiwan and ROCHESTER, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- Vuzix® Corporation (Nasdaq: VUZI), ("Vuzix"), a leading supplier of AI-powered smart glasses, waveguides and Augmented Reality (AR) technologies and Himax Technologies, Inc. (Nasdaq: HIMX …

Star Equity Holdings, Inc. Announces 2025 First Quarter Financial Results

Star Equity Holdings, Inc. Announces 2025 First Quarter Financial Results

Q1 2025 revenues increased to $12.9 million vs. $9.1 million in Q1 2024 Alliance Drilling Tools acquisition marks entry into Energy Services Quarter-end Building Solutions backlog stands at record $27.9 million OLD GREENWICH, Conn., May 14, 2025 (GLOBE …

Robex Kiniero Project on Track for First Gold in Q4

Robex Kiniero Project on Track for First Gold in Q4

HIGHLIGHTS: Construction at Robex’s Kiniero Gold Project, Guinea, remains on schedule and budget - first gold pour on track for Q4 CY25. Project remains LTI free (lost time injury). Phase 1 grade control drilling at Mansounia commenced on 18 March 2025 …

NETSOL Technologies Reports Third Quarter Fiscal 2025 Results

NETSOL Technologies Reports Third Quarter Fiscal 2025 Results

Total net revenues for Q3’25 increased by 13%, reaching $17.5 million, when compared with Q3’24. Total service revenue increased 24% in Q3’25, reaching $9.7 million, when compared with Q3,’24. Total subscription (SaaS and Cloud) and support revenues …

Brag House Continues Action to Protect Stockholders Against Potential Illegal Naked Short Selling

Brag House Continues Action to Protect Stockholders Against Potential Illegal Naked Short Selling

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Brag House Holdings, Inc. (NASDAQ: TBH) (“Brag House” or the “Company”), the premier Gen Z engagement platform that operates at the intersection of gaming, college sports, and social interaction, today announced …

CleanCore Solutions, Inc. (ZONE) Achieves 77.7% Year-Over-Year Revenue Growth for the Third Quarter of Fiscal 2025

CleanCore Solutions, Inc. (ZONE) Achieves 77.7% Year-Over-Year Revenue Growth for the Third Quarter of Fiscal 2025

Omaha, NE, May 14, 2025 (GLOBE NEWSWIRE) -- CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), developer of patented technology that works as a safe and low-cost replacement for traditional cleaning chemicals, today reported …

Blum Holdings Inc. Reports First Quarter 2025 Financial Results

Blum Holdings Inc. Reports First Quarter 2025 Financial Results

DOWNEY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company and cannabis operator, announced its financial results for the …

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary …

FDCTech Reports Over 58% Year-over-Year Revenue Growth in Q1 2025 Driven by Strong Performance Across All Business Segments

FDCTech Reports Over 58% Year-over-Year Revenue Growth in Q1 2025 Driven by Strong Performance Across All Business Segments

Q1 2025 Highlights Show Continued Growth and Operating Profitability.  Irvine, CA, May 14, 2025 (GLOBE NEWSWIRE) -- FDCTech, Inc. ("FDC" or the "Company," PINK: FDCT), a fintech-driven firm specializing in acquiring and scaling small to mid-size legacy …

Safe & Green Holdings Corp. Provides Corporate Update

Safe & Green Holdings Corp. Provides Corporate Update

MIAMI, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Safe …

Antalpha Announces Pricing of Initial Public Offering

Antalpha Announces Pricing of Initial Public Offering

SINGAPORE, May 14, 2025 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (“Antalpha” or the “Company”) today announced the pricing of its initial public offering of 3,850,000 ordinary shares at a price to the public of $12.80 per ordinary share. The …

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 Data presented at recent congresses reinforces the potential …

Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing

Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing

IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the first and only U.S. Food and Drug Administration (FDA) cleared direct-to-consumer (DTC) test for celiac disease genetics, today announced a commercial …

Powerdyne International Inc. Announces A letter to the Shareholders update

Powerdyne International Inc. Announces A letter to the Shareholders update

North Reading, MA, May 14, 2025 (GLOBE NEWSWIRE) -- Powerdyne International, Inc. (Ticker: PWDY) ("Powerdyne" and / or the “Company”) announces A Letter to the Shareholders Update. Dear Shareholders, We would like to thank all our shareholders for their …

DeFi Development Corp. Reports First Quarter 2025 Financial Results and Provides Strategic Update on Solana Treasury Activity

DeFi Development Corp. Reports First Quarter 2025 Financial Results and Provides Strategic Update on Solana Treasury Activity

BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (“DeFi Dev Corp” or the “Company”), a public-market vehicle focused on long-term Solana (“SOL”) accumulation, today announced financial results for the first quarter …

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 -- -- Cash resources of $42.2 million as of March 31, 2025, expected to fund operations into 1Q 2026 -- …

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing …

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service